Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: Possible involvement of N-type calcium channel in podocyte

Journal of Hypertension

Volumn 28, Issue 5, 2010, Pages 1034-1043

  Fan, Yu Yan ^a   Kohno, Masakazu ^a   Nakano, Daisuke ^a   Ohsaki, Hiroyuki ^b   Kobori, Hiroyuki ^c   Suwarni, Diah ^a   Ohashi, Naro ^c   Hitomi, Hirofumi ^a   Asanuma, Katsuhiko ^d   Noma, Takahisa ^a   Tomino, Yasuhiko ^d   Fujita, Toshiro ^e   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II; Oxidative stress; SHR ND mcr cp

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; CALCIUM CHANNEL N TYPE; CILNIDIPINE; CREATININE; DESMIN; GLUCOSE; HYDROETHIDINE; NEPHRIN; PODOCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; METABOLIC SYNDROME X; NEPHROBLASTOMA; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77951287431     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328336ade3     Document Type: Article

References (44)

1. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of nontraditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANESIII). Ann Epidemiol 2004; 14:686-695. (Pubitemid 39233630)
2. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134-2140. (Pubitemid 41716445)
3. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17:S206-S212. (Pubitemid 44865250)
4. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, et al. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007; 20:565-572. (Pubitemid 46691290)
5. Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24:377-383. (Pubitemid 32791814)
6. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27:379-385. (Pubitemid 38996928)
7. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72:1543-1549. (Pubitemid 350199443)
8. Varagic J, Susic D, Frohlich ED. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens 2002; 20:317-322. (Pubitemid 34913798)
9. Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002; 20:993-1000. (Pubitemid 34913681)
10. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101:1-13. (Pubitemid 41159949)
11. Konda T, EnomotoA,TakaharaA,Yamamoto H.Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29:933-937.
12. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25:2178-2183. (Pubitemid 47476317)
13. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711. (Pubitemid 41725107)
14. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens 2008; 26:1849-1859.
15. Pardo NE, Hajela RK, Atchison WD. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1. 2) Ca2\+ channels. J Pharmacol Exp Ther 2006; 319:1009-1020.
16. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 2008; 73:446-455. (Pubitemid 351186294)
17. Ekuni D, Firth JD, Putnins EE. Regulation of epithelial cell growth factor receptor protein and gene expression using a rat periodontitis model. J Periodontal Res 2006; 41:340-349. (Pubitemid 44392306)
18. Rahman M, Nishiyama A, Guo P, Nagai Y, Zhang GX, Fujisawa Y, et al. Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. J Pharmacol Exp Ther 2006; 318:1323-1329. (Pubitemid 44268342)
19. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16:2073-2080. (Pubitemid 41716438)
20. Kimura S, Zhang GX, Nishiyama A, Nagai Y, Nakagawa T, Miyanaka H, et al. D-allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats. J Hypertens 2005; 23:1887-1894. (Pubitemid 41830429)
21. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002; 277:19952-19960.
22. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236:248-258. (Pubitemid 27452369)
23. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001; 59:179-189. (Pubitemid 32055226)
24. Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 2003; 113:343-355. (Pubitemid 36556116)
25. Andreasen D, Jensen BL, Hansen PB, Kwon TH, Nielsen S, Skott O. The alpha(1G)-subunit of a voltage-dependent Ca(2\+) channel is localized in rat distal nephron and collecting duct. Am J Physiol Renal Physiol 2000; 279:F997-F1005. (Pubitemid 32001620)
26. Zhao PL, Wang XT, Zhang XM, Cebotaru V, Cebotaru L, Guo G, et al. Tubular and cellular localization of the cardiac L-type calcium channel in rat kidney. Kidney Int 2002; 61:1393-1406. (Pubitemid 34304500)
27. Murakami M, Ohba T, Xu F, Satoh E, Miyoshi I, Suzuki T, et al. Modified sympathetic nerve system activity with overexpression of the voltage-dependent calcium channel beta3 subunit. J Biol Chem 2008; 283:24554-24560.
28. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295:F1589-F1600.
29. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323:85-93. (Pubitemid 47443257)
30. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61:186-194. (Pubitemid 34075146)
31. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008; 51:474-480. (Pubitemid 351156435)
32. Hsu HH, Hoffmann S, Endlich N, Velic A, Schwab A, Weide T, et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med 2008; 86:1379-1394.
33. Hishikawa K, Takase O, Idei M, Fujito T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76:230-231.
34. Nitschke R, Henger A, Ricken S, Gloy J, Muller V, Greger R, et al. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int 2000; 57:41-49. (Pubitemid 30227752)
35. Huber TB, Gloy J, Henger A, Schollmeyer P, Greger R, Mundel P, et al. Catecholamines modulate podocyte function. J Am Soc Nephrol 1998; 9:335-345. (Pubitemid 28122858)
36. Nitschke R, Henger A, Ricken S, Muller V, Kottgen M, Bek M, et al. Acetylcholine increases the free intracellular calcium concentration in podocytes in intact rat glomeruli via muscarinic M(5) receptors. J Am Soc Nephrol 2001; 12:678-687. (Pubitemid 32246695)
37. Hsieh TJ, Fustier P, Wei CC, Zhang SL, Filep JG, Tang SS, et al. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J Endocrinol 2004; 183:535-550. (Pubitemid 40057584)
38. Brezniceanu ML, Liu F, Wei CC, Tran S, Sachetelli S, Zhang SL, et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007; 71:912-923. (Pubitemid 46663797)
39. Liu F, Brezniceanu ML, Wei CC, Chenier I, Sachetelli S, Zhang SL, et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19:269-280. (Pubitemid 351240649)
40. Liu F, Wei CC, Wu SJ, Chenier I, Zhang SL, Filep JG, et al. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 2009; 75:156-166.
41. Bie P, Damkjaer M. Renin secretion and total body sodium: pathways of integrative control. Clin Exp Pharmacol Physiol 2009. [Epub ahead of print] doi:10.1111/j.1440-1681.2009.05316.x
42. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 2009; 30:155-161.
43. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2\+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100:342-353. (Pubitemid 46272406)
44. Konno Y, Kimura K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J 2008; 49:723-732.